BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trpkov K, Williamson SR, Gao Y, Martinek P, Cheng L, Sangoi AR, Yilmaz A, Wang C, San Miguel Fraile P, Perez Montiel DM, Bulimbasić S, Rogala J, Hes O. Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity? Histopathology 2019;75:174-84. [PMID: 30895640 DOI: 10.1111/his.13865] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Tzortzakakis A, Papathomas T, Gustafsson O, Gabrielson S, Trpkov K, Ekström-Ehn L, Arvanitis A, Holstensson M, Karlsson M, Kokaraki G, Axelsson R. 99mTc-Sestamibi SPECT/CT and histopathological features of oncocytic renal neoplasia. Scand J Urol 2022;:1-8. [PMID: 36065481 DOI: 10.1080/21681805.2022.2119273] [Reference Citation Analysis]
2 Xia QY, Wang XT, Zhao M, He HY, Fang R, Ye SB, Li R, Wang X, Zhang RS, Lu ZF, Ma HH, Wang ZY, Rao Q. TSC/MTOR-associated Eosinophilic Renal Tumors Exhibit a Heterogeneous Clinicopathologic Spectrum: A Targeted Next-generation Sequencing and Gene Expression Profiling Study. Am J Surg Pathol 2022. [PMID: 35980750 DOI: 10.1097/PAS.0000000000001955] [Reference Citation Analysis]
3 Argani P, Matoso A, Pallavajjalla A, Haley L, Tseh-Lin M, Ng J, Chow CW, Lotan T, Mehra R. Xanthomatous Giant Cell Renal Cell Carcinoma: Another Morphologic Form of TSC-associated Renal Cell Carcinoma. Am J Surg Pathol 2022. [PMID: 35941720 DOI: 10.1097/PAS.0000000000001940] [Reference Citation Analysis]
4 Amin MB, McKenney JK, Martignoni G, Campbell SC, Pal S, Tickoo SK. Low grade oncocytic tumors of the kidney: a clinically relevant approach for the workup and accurate diagnosis. Mod Pathol 2022. [PMID: 35896615 DOI: 10.1038/s41379-022-01108-5] [Reference Citation Analysis]
5 Alaghehbandan R, Williamson SR, McKenney JK, Hes O. The Histologic Diversity of Chromophobe Renal Cell Carcinoma With Emphasis on Challenges Encountered in Daily Practice. Adv Anat Pathol 2022;29:194-207. [PMID: 35470289 DOI: 10.1097/PAP.0000000000000349] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Mirkheshti N, Farrukh N, Legesse T, Rowe SP, Gordetsky J, Hussain A. Renal oncocytoma: a challenging diagnosis. Current Opinion in Oncology 2022;34:243-52. [DOI: 10.1097/cco.0000000000000829] [Reference Citation Analysis]
7 Paner GP, Chumbalkar V, Montironi R, Moch H, Amin MB. Updates in Grading of Renal Cell Carcinomas Beyond Clear Cell Renal Cell Carcinoma and Papillary Renal Cell Carcinoma. Adv Anat Pathol 2022;29:117-30. [PMID: 35275846 DOI: 10.1097/PAP.0000000000000341] [Reference Citation Analysis]
8 Tomaszewski Z, Littler Y. Unclassified Oncocytic Renal Neoplasm with Rib and Liver Metastases: Metastatic Oncocytoma? Int J Surg Pathol 2022;:10668969221084265. [PMID: 35274993 DOI: 10.1177/10668969221084265] [Reference Citation Analysis]
9 Hes O, Trpkov K. Do we need an updated classification of oncocytic renal tumors? : Emergence of low-grade oncocytic tumor (LOT) and eosinophilic vacuolated tumor (EVT) as novel renal entities. Mod Pathol 2022. [PMID: 35273336 DOI: 10.1038/s41379-022-01057-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Zhang H, Xia Q, Wang S, Shi M, Wang S. Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity. Virchows Arch. [DOI: 10.1007/s00428-022-03283-x] [Reference Citation Analysis]
11 Pivovarcikova K, Alaghehbandan R, Vanecek T, Ohashi R, Pitra T, Hes O. TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background. Biomedicines 2022;10:322. [DOI: 10.3390/biomedicines10020322] [Reference Citation Analysis]
12 Argani P, Mehra R. Renal cell carcinoma associated with tuberous sclerosis complex (TSC)/mammalian target of rapamycin (MTOR) genetic alterations. Mod Pathol 2022. [PMID: 35046523 DOI: 10.1038/s41379-021-00971-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
13 Sheenu V, Paul R, Pushpa M, Ami E, Rashmi R, Iona M, Elizabeth M. Histopathological spectrum of adult renal tumours: A Single center experience and review of literature. Indian J Pathol Microbiol 2022;0:0. [DOI: 10.4103/ijpm.ijpm_53_21] [Reference Citation Analysis]
14 Fuchs TL, Maclean F, Turchini J, Vargas AC, Bhattarai S, Agaimy A, Hartmann A, Kao C, Ellis C, Bonert M, Leroy X, Kunju LP, Schwartz L, Matsika A, Williamson SR, Rao P, Divatia M, Guarch R, Algaba F, Balancin ML, Zhou M, Samaratunga H, da Cunha IW, Brimo F, Ryan A, Clouston D, Aron M, O’donnell M, Chan E, Hirsch MS, Moch H, Pang C, Wah C, Yin W, Perry-keene J, Yilmaz A, Chou A, Clarkson A, van der Westhuizen G, Morrison E, Zwi J, Hes O, Trpkov K, Gill AJ. Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients. Mod Pathol. [DOI: 10.1038/s41379-021-00998-1] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
15 Alaghehbandan R, Przybycin CG, Verkarre V, Mehra R. Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates. Asian Journal of Urology 2021. [DOI: 10.1016/j.ajur.2021.11.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Akgul M, Williamson SR. Immunohistochemistry for the diagnosis of renal epithelial neoplasms. Semin Diagn Pathol 2022;39:1-16. [PMID: 34823973 DOI: 10.1053/j.semdp.2021.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Mohanty SK, Satapathy A, Aggarwal A, Mishra SK, Sampat NY, Sharma S, Williamson SR. Oncocytic renal neoplasms with diffuse keratin 7 immunohistochemistry harbor frequent alterations in the mammalian target of rapamycin pathway. Mod Pathol 2021. [PMID: 34802045 DOI: 10.1038/s41379-021-00969-6] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
18 Wang G, Amin MB, Grossmann P, Ptáková N, Hayes M, Hartmann A, Agaimy A, Lopez JI, Michal M, Hes O. Renal cell tumor with sex-cord/gonadoblastoma-like features: analysis of 6 cases. Virchows Arch 2021. [PMID: 34775513 DOI: 10.1007/s00428-021-03235-x] [Reference Citation Analysis]
19 Henske EP, Cornejo KM, Wu CL. Renal Cell Carcinoma in Tuberous Sclerosis Complex. Genes (Basel) 2021;12:1585. [PMID: 34680979 DOI: 10.3390/genes12101585] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
20 Gupta S, Rowsey RA, Cheville JC, Jimenez RE. Morphologic overlap between low-grade oncocytic tumor and eosinophilic variant of chromophobe renal cell carcinoma. Hum Pathol 2021:S0046-8177(21)00178-7. [PMID: 34634270 DOI: 10.1016/j.humpath.2021.09.010] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Kapur P, Gao M, Zhong H, Chintalapati S, Mitui M, Barnes SD, Zhou Q, Miyata J, Carrillo D, Malladi VS, Rakheja D, Pedrosa I, Xu L, Kinch L, Brugarolas J. Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney. Mod Pathol 2021. [PMID: 34538873 DOI: 10.1038/s41379-021-00896-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Morini A, Drossart T, Timsit MO, Sibony M, Vasiliu V, Gimenez-Roqueplo AP, Favier J, Badoual C, Mejean A, Burnichon N, Verkarre V. Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1. Mod Pathol 2021. [PMID: 34531523 DOI: 10.1038/s41379-021-00906-7] [Reference Citation Analysis]
23 Polifka I, Ohashi R, Moch H. [Oncocytic tumours of the kidney-new differential diagnoses]. Pathologe 2021;42:551-9. [PMID: 34468818 DOI: 10.1007/s00292-021-00979-w] [Reference Citation Analysis]
24 Bergmann L, Weber S, Hartmann A, Ahrens M. Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview. Expert Rev Anticancer Ther 2021;:1-14. [PMID: 34291700 DOI: 10.1080/14737140.2021.1959319] [Reference Citation Analysis]
25 Baniak N, Barletta JA, Hirsch MS. Key Renal Neoplasms With a Female Predominance. Adv Anat Pathol 2021;28:228-50. [PMID: 34009777 DOI: 10.1097/PAP.0000000000000301] [Reference Citation Analysis]
26 Akgul M, Al-Obaidy KI, Cheng L, Idrees MT. Low-grade oncocytic tumour expands the spectrum of renal oncocytic tumours and deserves separate classification: a review of 23 cases from a single tertiary institute. J Clin Pathol 2021:jclinpath-2021-207478. [PMID: 34168073 DOI: 10.1136/jclinpath-2021-207478] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
27 Lerma LA, Schade GR, Tretiakova MS. Co-existence of ESC-RCC, EVT, and LOT as synchronous and metachronous tumors in six patients with multifocal neoplasia but without clinical features of tuberous sclerosis complex. Hum Pathol 2021;116:1-11. [PMID: 34153307 DOI: 10.1016/j.humpath.2021.06.002] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
28 Al-Obaidy KI, Cheng L. Renal oncocytoma with adverse pathologic features: a clinical and pathologic study of 50 cases. Mod Pathol 2021. [PMID: 34103666 DOI: 10.1038/s41379-021-00849-z] [Reference Citation Analysis]
29 Munari E, Settanni G, Caliò A, Segala D, Lonardi S, Sandrini S, Vacca P, Tumino N, Marconi M, Brunelli M, Gobbo S, Netto GJ, Moretta L, Zamboni G, Martignoni G. TSC loss is a clonal event in eosinophilic solid and cystic renal cell carcinoma: a multiregional tumor sampling study. Mod Pathol 2021. [PMID: 33990704 DOI: 10.1038/s41379-021-00816-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Kwon R, Argani P, Epstein JI, Lombardo KA, Wang X, Pierorazio PM, Mehra R, Matoso A. Contemporary Characterization and Recategorization of Adult Unclassified Renal Cell Carcinoma. Am J Surg Pathol 2021;45:450-62. [PMID: 33239504 DOI: 10.1097/PAS.0000000000001629] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Yambayev I, Sullivan TB, Suzuki K, Zhao Q, Higgins SE, Yilmaz OH, Litle VR, Moreira P, Servais EL, Stock CT, Quadri SM, Williamson C, Rieger-Christ KM, Burks EJ. Pulmonary Adenocarcinomas of Low Malignant Potential: Proposed Criteria to Expand the Spectrum Beyond Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. Am J Surg Pathol 2021;45:567-76. [PMID: 33177339 DOI: 10.1097/PAS.0000000000001618] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Kravtsov O, Gupta S, Cheville JC, Sukov WR, Rowsey R, Herrera-Hernandez LP, Lohse CM, Knudson R, Leibovich BC, Jimenez RE. Low-Grade Oncocytic Tumor of Kidney (CK7-Positive, CD117-Negative): Incidence in a single institutional experience with clinicopathological and molecular characteristics. Hum Pathol 2021;114:9-18. [PMID: 33961838 DOI: 10.1016/j.humpath.2021.04.013] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
33 Polifka I, Agaimy A, Moch H, Hartmann A. [Histological subtypes of renal cell carcinoma : Overview and new developments]. Pathologe 2021;42:294-304. [PMID: 33825093 DOI: 10.1007/s00292-021-00937-6] [Reference Citation Analysis]
34 Cimadamore A, Cheng L, Scarpelli M, Massari F, Mollica V, Santoni M, Lopez-Beltran A, Montironi R, Moch H. Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review. Transl Androl Urol 2021;10:1506-20. [PMID: 33850785 DOI: 10.21037/tau-20-1150] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
35 Ishikawa N, Kimura N, Yoshida T, Yoshimura I, Nakahara K, Tsuzuki T, Tokunaga O. A Case of Low-Grade Oncocytic Tumor/Chromophobe Renal Cell Carcinoma (Oncocytic Variant) of the Kidney. Case Rep Pathol 2021;2021:6684777. [PMID: 33680526 DOI: 10.1155/2021/6684777] [Reference Citation Analysis]
36 Trpkov K, Williamson SR, Gill AJ, Adeniran AJ, Agaimy A, Alaghehbandan R, Amin MB, Argani P, Chen Y, Cheng L, Epstein JI, Cheville JC, Comperat E, da Cunha IW, Gordetsky JB, Gupta S, He H, Hirsch MS, Humphrey PA, Kapur P, Kojima F, Lopez JI, Maclean F, Magi-galluzzi C, Mckenney JK, Mehra R, Menon S, Netto GJ, Przybycin CG, Rao P, Rao Q, Reuter VE, Saleeb RM, Shah RB, Smith SC, Tickoo S, Tretiakova MS, True L, Verkarre V, Wobker SE, Zhou M, Hes O. Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol 2021;34:1167-84. [DOI: 10.1038/s41379-021-00737-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
37 Athanazio DA, Amorim LS, da Cunha IW, Leite KRM, da Paz AR, de Paula Xavier Gomes R, Tavora FRF, Faraj SF, Cavalcanti MS, Bezerra SM. Classification of renal cell tumors – current concepts and use of ancillary tests: recommendations of the Brazilian Society of Pathology. Surg Exp Pathol 2021;4. [DOI: 10.1186/s42047-020-00084-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Gupta S, Jimenez RE, Herrera-Hernandez L, Lohse CM, Thompson RH, Boorjian SA, Leibovich BC, Cheville JC. Renal Neoplasia in Tuberous Sclerosis: A Study of 41 Patients. Mayo Clin Proc 2021;96:1470-89. [PMID: 33526281 DOI: 10.1016/j.mayocp.2020.11.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
39 Tjota MY, Wanjari P, Segal J, Antic T. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study. Hum Pathol 2021;115:84-95. [PMID: 33352195 DOI: 10.1016/j.humpath.2020.12.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
40 Karashima T, Kuroda N, Taguchi T, Fukuhara H, Kuno T, Tamura K, Hiroi M, Inoue K, Yamaguchi T. Oncocytic variant, a novel subtype of chromophobe renal cell carcinoma: a report of two cases and a literature review. Int Cancer Conf J 2021;10:100-6. [PMID: 33782641 DOI: 10.1007/s13691-020-00459-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Papathomas T, Tzortzakakis A, Sun N, Erlmeier F, Feuchtinger A, Trpkov K, Bazarova A, Arvanitis A, Wang W, Bozoky B, Kokaraki G, Axelsson R, Walch A. In Situ Metabolomics Expands the Spectrum of Renal Tumours Positive on 99mTc-sestamibi Single Photon Emission Computed Tomography/Computed Tomography Examination. Eur Urol Open Sci 2020;22:88-96. [PMID: 34337482 DOI: 10.1016/j.euros.2020.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Moch H, Ohashi R. Chromophobe renal cell carcinoma: current and controversial issues. Pathology 2021;53:101-8. [PMID: 33183792 DOI: 10.1016/j.pathol.2020.09.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
43 de Andrade Melo CGR, Xavier MVN, Pimenta IS, Athanazio DA. Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive). Surg Exp Pathol 2020;3. [DOI: 10.1186/s42047-020-00074-z] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Guo Q, Liu N, Wang F, Guo Y, Yang B, Cao Z, Wang Y, Wang Y, Zhang W, Huang Q, Zhao W, Liu C, Qu T, Li L, Cao L, Ren D, Meng B, Qi L, Wang C, Cao W. Characterization of a distinct low-grade oncocytic renal tumor (CD117-negative and cytokeratin 7-positive) based on a tertiary oncology center experience: the new evidence from China. Virchows Arch 2021;478:449-58. [PMID: 32918598 DOI: 10.1007/s00428-020-02927-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
45 Kriegsmann M, Casadonte R, Maurer N, Stoehr C, Erlmeier F, Moch H, Junker K, Zgorzelski C, Weichert W, Schwamborn K, Deininger SO, Gaida M, Mechtersheimer G, Stenzinger A, Schirmacher P, Hartmann A, Kriegsmann J, Kriegsmann K. Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy. J Cancer 2020;11:6081-9. [PMID: 32922548 DOI: 10.7150/jca.47698] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Tong K, Hu Z. FOXI1 expression in chromophobe renal cell carcinoma and renal oncocytoma: a study of The Cancer Genome Atlas transcriptome-based outlier mining and immunohistochemistry. Virchows Arch 2021;478:647-58. [PMID: 32812119 DOI: 10.1007/s00428-020-02900-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
47 Abdessater M, Kanbar A, Comperat E, Dupont-Athenor A, Alechinsky L, Mouton M, Sebe P. Renal Oncocytoma: An Algorithm for Diagnosis and Management. Urology 2020;143:173-80. [PMID: 32512107 DOI: 10.1016/j.urology.2020.05.047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
48 Siadat F, Trpkov K. ESC, ALK, HOT and LOT: Three Letter Acronyms of Emerging Renal Entities Knocking on the Door of the WHO Classification. Cancers (Basel) 2020;12:E168. [PMID: 31936678 DOI: 10.3390/cancers12010168] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
49 Mikami S, Kuroda N, Nagashima Y, Ohe C, Hayashi H, Mizuno R, Oya M, Kameyama K. Classification of solid renal tumor with oncocytic/eosinophilic cytoplasm: is hybrid oncocytic/chromophobe renal tumor a subtype of oncocytoma, chromophobe renal cell carcinoma, or a distinct tumor entity? Ann Transl Med 2019;7:S350. [PMID: 32016068 DOI: 10.21037/atm.2019.09.77] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
50 Ohashi R, Martignoni G, Hartmann A, Caliò A, Segala D, Stöhr C, Wach S, Erlmeier F, Weichert W, Autenrieth M, Schraml P, Rupp NJ, Ohe C, Otsuki Y, Kawasaki T, Kobayashi H, Kobayashi K, Miyazaki T, Shibuya H, Usuda H, Umezu H, Fujishima F, Furusato B, Osakabe M, Sugai T, Kuroda N, Tsuzuki T, Nagashima Y, Ajioka Y, Moch H. Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme. Virchows Arch 2020;476:409-18. [PMID: 31760491 DOI: 10.1007/s00428-019-02710-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
51 Ohashi R, Schraml P, Angori S, Batavia AA, Rupp NJ, Ohe C, Otsuki Y, Kawasaki T, Kobayashi H, Kobayashi K, Miyazaki T, Shibuya H, Usuda H, Umezu H, Fujishima F, Furusato B, Osakabe M, Sugai T, Kuroda N, Tsuzuki T, Nagashima Y, Ajioka Y, Moch H. Classic Chromophobe Renal Cell Carcinoma Incur a Larger Number of Chromosomal Losses Than Seen in the Eosinophilic Subtype. Cancers (Basel) 2019;11:E1492. [PMID: 31623347 DOI: 10.3390/cancers11101492] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
52 Lau HD, Chan E, Fan AC, Kunder CA, Williamson SR, Zhou M, Idrees MT, Maclean FM, Gill AJ, Kao C. A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 Patients. American Journal of Surgical Pathology 2020;44:98-110. [DOI: 10.1097/pas.0000000000001372] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]